Photocure (DB:PHS) - Aandelenkoers, Nieuws & Analyse

PHS Overzicht aandelen

PHS fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	4/6
Prestaties in het verleden	3/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 87.2% onder onze schatting van de reële waarde

De winst zal naar verwachting met 94.94% per jaar groeien

Dit jaar winstgevend geworden

Risicoanalyse

Aandelen zijn zeer illiquide

Photocure ASA Concurrenten

Pierrel

DB:2FJ0

€92.8m

PharmaSGP Holding

XTRA:PSG

€287.8m

MPH Health Care

DB:93M1

€105.3m

Dermapharm Holding

XTRA:DMP

€2.0b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Photocure
Historische aandelenkoersen
Huidige aandelenkoers	NOK 4.41
52 Week Hoogtepunt	NOK 4.84
52 Week Laag	NOK 4.28
Bèta	0.99
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	-62.72%
5 jaar verandering	n/a
Verandering sinds IPO	-25.88%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	PHS	DE Pharmaceuticals	DE Markt
7D	0%	1.4%	0.8%
1Y	n/a	-18.4%	9.1%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe PHS presteerde ten opzichte van de German Pharmaceuticals.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe PHS presteerde ten opzichte van de German markt.

Prijsvolatiliteit

Is PHS's price volatile compared to industry and market?
PHS volatility
PHS Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van PHS is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van PHS in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1993	102	Dan Schneider	www.photocure.com

Photocure ASA houdt zich, samen met haar dochterondernemingen, bezig met onderzoek, ontwikkeling, productie, distributie, marketing en verkoop van farmaceutische producten in Scandinavische landen, Duitsland, Frankrijk, Oostenrijk, het Verenigd Koninkrijk, de Benelux, Italië, andere Europese landen, Canada en de Verenigde Staten. Het bedrijf is actief via de segmenten Commercial Franchise en Development Portfolio. Het bedrijf biedt Hexvix/Cysview aan voor de detectie en behandeling van blaaskanker.

Photocure ASA Samenvatting

Hoe verhouden de winst en inkomsten van Photocure zich tot de beurswaarde?
PHS fundamentele statistieken
Marktkapitalisatie	€117.53m
Inkomsten(TTM)	€1.22m
Inkomsten(TTM)	€45.18m

96.6x

Koers/Winstverhouding

2.6x

P/S-verhouding

Is PHS overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
PHS resultatenrekening (TTM)
Inkomsten	NOK 526.25m
Kosten van inkomsten	NOK 29.11m
Brutowinst	NOK 497.15m
Overige uitgaven	NOK 482.98m
Inkomsten	NOK 14.16m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.52
Brutomarge	94.47%
Nettowinstmarge	2.69%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde PHS op de lange termijn?

Bekijk historische prestaties en vergelijking

PHS Overzicht aandelen

Beloningen

Risicoanalyse

Photocure ASA Concurrenten

DB:2FJ0

€92.8m

XTRA:PSG

€287.8m

DB:93M1

€105.3m

XTRA:DMP

€2.0b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023)

Photocure ASA Announces Board Appointments

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Less than half of directors are independent

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Recent updates

Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023)

Photocure ASA Announces Board Appointments

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Less than half of directors are independent

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China

Photocure ASA Announces Change of Board Composition

Less than half of directors are independent

Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint

Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.81 loss in 1Q 2022)

Forecast breakeven date pushed back to 2024

Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021)

Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023

Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy

Third quarter 2022 earnings released: kr0.37 loss per share (vs kr0.27 loss in 3Q 2021)

Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc

PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S

Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology

Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Second quarter 2022 earnings released: kr0.68 loss per share (vs kr0.40 loss in 2Q 2021)

Second quarter 2022 earnings released: kr0.68 loss per share (vs kr0.40 loss in 2Q 2021)

Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States

Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022.

Full year 2021 earnings released: kr1.15 loss per share (vs kr0.91 loss in FY 2020)

Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S

Third quarter 2021 earnings released: kr0.27 loss per share (vs kr0.23 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020)

Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology

Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on June 10, 2020.

Photocure ASA Suspends Guidance for 2023

New 90-day high: €10.40

Photocure ASA to Report Q3, 2021 Results on Nov 17, 2021

Asieris Pharmaceuticals and Photocure ASA Expands Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan

Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan

New 90-day high: €9.02

Photocure Announces New Cevira Patent In Europe

Photocure Launches European Hexvix Operations

Photocure ASA Provides Revenue Guidance for the Year 2020

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Photocure ASA Samenvatting

96.6x

2.6x

Inkomsten en omzet